-
[show abstract]
[hide abstract]
ABSTRACT: Adjuvant chemotherapy is used as an alternative treatment for non-small cell lung cancer (NSCLC); however, the efficiency of post-pneumonectomy adjuvant chemotherapy in NSCLC has not been clarified. In the present study, patients who benefited from adjuvant chemotherapy with TP/NP/GP were identified. A total of 217 patients who underwent pneumonectomy were identified in this study. Of these, 87 underwent pneumonectomy combined with adjuvant chemotherapy (TP/NP/GP regimen) and 130 underwent pneumonectomy only in the initial management. The primary endpoint of the present study was overall survival. Actuarial survival analysis was conducted using the Kaplan-Meier method. Postoperative adjuvant chemotherapy significantly improved the survival rate of patients who underwent left pneumonectomy and in patients with a preoperative forced expiratory volume in 1 sec (FEV1) greater than or equal to 21. Age had no effect on the survival rate of patients with or without postoperative adjuvant therapy. Post-pneumonectomy adjuvant chemotherapy is an efficient therapy in NSCLC for patients with preoperative FEV1 greater than or equal to 21 or who received left pneumonectomy.
Oncology letters 12/2012; 4(6):1349-1353. · 0.11 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: To study the prognosis and prognostic factors of non-small-cell lung carcinoma (NSCLC) according the new TNM stage system.
Clinic data of 1638 inpatient cases admitted from January 2001 to January 2005 were retrospectively reviewed. There were 1083 male and 555 female patients in the study and the average age was 59.5 years. All the patients received surgical procedures.
The overall 1, 3, 5-year survival rate was 80.0%, 52.3%, 39.0%. The main prognostic factors were bronchial stump, operation type, T stage, N stage, the number of lymph nodes (LNs) in lymph nodes dissection (1 - 10, 11 - 20, and > 20), overall N stations (< 4 and ≥ 4) and postoperative radiotherapy (all P < 0.05). Cox regression suggested that T stage (P = 0.000), N stage (P = 0.000), operation type (P = 0.001) and LNs (P = 0.013) were independent factors affecting the prognosis.
The overall survival rate of NSCLC is poor. T stage, N stage, operation type and LNs are independent factors affecting the prognosis.
Zhonghua wai ke za zhi [Chinese journal of surgery] 07/2011; 49(7):618-22.
-
[show abstract]
[hide abstract]
ABSTRACT: S100A8 and S100A9 are two members of the S100 protein family characterized by the presence of two Ca2+-binding sites of the EF-hand type. Previous studies suggested that the whole S100 family displays significant functions in tumor growth, progression and invasion. This study aimed to determine the expression of the two indices of the family, S100A8 and S100A9, in lung cancer tissues and normal lung tissues and its correlation with clinical features.
A total of 60 cases with a variety of clinical data that were diagnosed with different histological subtypes of lung cancer were investigated. Semi-quantitative reverse transcriptase-PCR (Sq-Rt-PCR) and immunohistochemical staining of cancer, adjacent and peripheral lung tissues were executed to distinguish the expression patterns of S100A8 and S100A9 and to further clarify their correlation with clinical features.
Immunohistochemical staining of both proteins showed a significant up-regulation in lung cancer tissue (S100A8, S100A9, P<0.0001), and PCR revealed that the levels of S100A8 and S100A9 expression were significantly higher in lung cancer tissues (S100A8 P=0.002/0.004; S100A9 P=0.022/0.026). The higher expression was found to be correlated with the clinical characteristics of adenocarcinoma, inflammation and stage IV lesion.
S100A8, S100A9 up-regulation was found in the lung adenocarcinoma and end stage lung cancer tissue, the correlation of which with their higher expression in inflammatory lung tissues may indicate the collaborative effect of inflammation on the progression of cancer.
Chinese medical journal 08/2010; 123(16):2215-20. · 0.86 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: Multiple factors have been reported as affecting the prognosis, and they affect the therapeutic outcomes of stage I non-small-cell lung cancer (NSCLC) patients. Most studies focus on patients receiving combined-modality therapy, whereas there are few studies that focus on patients undergoing surgery alone. The aim of this study was to identify risk factors for disease relapse and unfavorable prognosis in stage I NSCLC patients treated with surgery alone.
A total of 315 stage I NSCLC patients who were treated with surgery alone as the definitive therapy were identified. Risk factors for disease relapse and unfavorable prognosis were estimated by univariate and multivariate analyses.
Sex, tumor pathologic stage, and cavitating lung cancer were identified as independent risk factors for relapse and overall survival using the multivariate analysis. Sex, tumor pathologic stage, and cavitating lung cancer were identified as independent risk factors for early relapse, and sex and cavitating lung cancer were independent risk factors for late relapse.
Tumor cavitation, pathologic stage IB, and being male are predictors of poor outcome for patients with stage I NSCLC who undergo resection.
World Journal of Surgery 01/2009; 33(3):497-504. · 2.36 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: To evaluate the efficacy and safety of an adjuvant chemotherapy regimen: XELOX (Capecitabine puls Oxaliplatin) used after curative resection for stage III colorectal cancer.
From Jan. 1998 to Jan. 2004, 256 cases with stage III colorectal cancer randomized received de Gramont, modified FOLFOX4 (mFOLFOX4) and XELOX regimens. The 3-year disease-free survival (DFS) and overall survival (OS) were compared within the three groups and relative prognosis factors within mFOLFOX4 and XELOX groups. Therapeutic adverse events were recorded and analyzed with Kaplan-Meier test.
98, 87 and 71 cases were respectively enrolled in the de Gramont, mFOLFOX4 and XELOX groups, mFOLFOX4 and XELOX had superior efficacy compared with de Gramont regimen. The two former could significantly improve 3-year DFS (79.7% vs. 66.2%, P = 0.015; 81.5% vs. 66.2%, P = 0.004) and medium survival time (40.2 mon vs. 37.8 mon, P = 0.024; 41.4 mon vs. 37.8 mon, P = 0.014). Meanwhile they could respectively decrease the ratio of recurrence risk by 18.0% (P = 0.024) and 21.0% (P = 0.003). The relative benefit of mFOLFOX4 versus XELOX didn't differ for 3-year DFS [hazard ratio (HR): 0.84, 95% confidence interval (CI): 0.79-1.12, P = 0.13] and OS (HR: 0.87, 95% CI: 0.84-1.06, P = 0.54). In the analysis of DFS in relative prognosis factors, XELOX had a better trend of survival advantage. mFOLFOX4 had higher adverse events within these regimens, especially in grade 3 or 4 neutropenia and peripheral neurologic adverse events.
XELOX maintains its efficacy and safety ratio in advanced colorectal cancer. Patients have good tolerance and compliance. The regiment is deserves to be applied in clinical treatment. Oxaliplatin;
Zhonghua zhong liu za zhi [Chinese journal of oncology] 02/2008; 30(2):147-50.
-
[show abstract]
[hide abstract]
ABSTRACT: Presently, whether non-small cell lung cancer (NSCLC) patients may benefit from adjuvant chemotherapy after left pneumonectomy is controversial. This study was to evaluate the efficacy of adjuvant chemotherapy after left pneumonectomy on NSCLC, and explore candidate patient selection for adjuvant chemotherapy.
Clinical data of 51 NSCLC patients received radical left pneumonectomy and adjuvant chemotherapy of TP/NP regimen and 102 patients received left pneumonectomy alone between Jan. 1997 and Jan. 2002 were compared.
The 1-, 3-, and 5-year survival rates were 88.2%, 54.9%, and 36.1% in adjuvant chemotherapy group, and 76.5%, 37.3%, and 23.9% in control group (P>0.05). For the patients at stage N2 or IIIA, the 1-, 3-, and 5-year survival rates were significantly higher in adjuvant chemotherapy group than in control group (P<0.05). For the patients with preoperative forced expiratory volume at the first second (FEV1) of >2 L, the 1-, 3-, and 5-year survival rates were significantly higher in adjuvant chemotherapy group than in control group (P<0.05). For the patients aged of >65 or < o r =65, there was no significant difference in survival between the two groups (P>0.05).
For the NSCLC patients at stage IIIA, N2 or with preoperative FEV1 of >2 L, adjuvant chemotherapy after left pneumonectomy may improve survival rate. For the patients with good pulmonary function, even aged patients, adjuvant chemotherapy is needed.
Ai zheng = Aizheng = Chinese journal of cancer 01/2008; 26(12):1365-8.
-
[show abstract]
[hide abstract]
ABSTRACT: To evaluate the distribution of CD4+ CD25+ regulatory T-cells (T-regs) in tumor-draining lymph nodes (TDLN) in patients with non-small cell lung caner (NSCLC), and to investigate the effect of CD4+ CD25+ T regulatory cells on the immune status of TDLN and the progression of NSCLC.
Regional tumor-draining lymph nodes of 53 NSCLC patients were resected during the operation. The percentage of CD4+ CD25+ T-regs as a subset of CD4+ T cells and CD8+ T cells were detected by immunofluorescence and regular immunohistochemistry, respectively. The level of cytokines TGF-beta1 and IL-10 was detected by real time quantitative RT-PCR.
CD4+ CD25+ T-regs in tumor-infiltrating lymph nodes from the patients with NSCLC accounted for 28.80% +/- 8.06% of total CD4+ T cells, and were significantly increased comparing with that (15.48% +/- 4.66%) in the tumor-free lymph nodes (P < 0.01). The percentage of CD4+ CD25+ T-regs in TDLN of NSCLC patients was negatively correlated with the amount of CD8+ T cells within the lymph nodes (r = -0. 756, P < 0.001), but positively correlated with the level of TGF-beta1 (r = 0.645, P < 0.001) and IL-10 (r = 0.769, P < 0.001). It also increased as NSCLC getting progressed, which was 30.42% +/- 7.47% in stage III versus 16.22% +/- 4.88% in stage I and III; 32.58% +/- 7.52% in N2 versus 22.76% +/- 4.67% in N1, with a significant difference between the two groups, respectively (P < 0.01).
The population of CD4+ CD25+ T regulatory cells in tumor-draining lymph nodes in patients with non-small cell lung caner is positively correlated with the progression and infiltration of lung cancer, which might provide new immunologic method to evaluate the progression and prognosis of non-small cell lung caner. The outcomes of biotherapy for NSCLC may be improved in the future through regulating the CD4+ CD25+ T regulatory cells.
Zhonghua zhong liu za zhi [Chinese journal of oncology] 12/2007; 29(12):922-6.
